Aegis Capital Believes Revance Therapeutics (NASDAQ: RVNC) Won’t Stop Here

By Austin Angelo

Aegis Capital analyst Difei Yang reiterated a Buy rating on Revance Therapeutics (NASDAQ: RVNC) today and set a price target of $36. The company’s shares closed yesterday at $24, close to its 52-week high of $25.

According to, Yang is a 4-star analyst with an average return of 6.5% and a 45.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Protalix Biotherapeutics, and Spectrum Pharmaceuticals.

Revance Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $36.

The company has a one year high of $25 and a one year low of $12.35. Currently, Revance Therapeutics has an average volume of 175.1K.

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RVNC in relation to earlier this year. Last month, Lauren Silvernail, the CFO, CBO & Secretary of RVNC bought 23,000 shares for a total of $200,100.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Revance Therapeutics, Inc. is a clinical stage specialty biopharmaceutical company, which engages on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. It focuses on the development of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne in August 10, 1999 and is headquartered in Newark, CA.